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ABSTRACT Idiopathic pulmonary fibrosis (IPF) is characterised by unpredictable disease course and
poor survival. After the introduction of novel antifibrotic drugs, the prognosis of patients with IPF is
probably changing.
FinnishIPF, a nationwide registry of carefully characterised patients, was initiated in Finland in 2011.
For the data analysis, we included 453 incident IPF patients diagnosed during 2011–2015. In this study, we
describe the demographics and prognosis of these real-life patients.
The median overall survival time of registered IPF patients was 4.5 years. The transplant-free survival at
1, 2, 3, 4 and 5 years was 95%, 83%, 70%, 58% and 45%, respectively. Smoking did not have any effect on
survival. 117 (26%) patients received pirfenidone or nintedanib. Patients who received ⩾6 months of
treatment had better survival compared with those who did not receive treatment but this difference
disappeared after age adjustment. The transplantation rate was 3%.
Although IPF is diagnosed in Finland at a older age, the prognosis is better than expected due to a
relatively well preserved lung function at diagnosis. Age and pulmonary function were identified as
independent predictors of survival in the entire IPF patient population as well as in patients who had
received antifibrotic treatment.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a disease with an unpredictable disease course and poor prognosis.
The usually quoted median survival of 2–3 years is based on studies from the 1990s and the early 2000s [1],
before the era of the new American Thoracic Society (ATS)/European Respiratory Society (ERS)
classification and the introduction of antifibrotic medication. More recent studies suggest that IPF patients
might live longer [2]: mortality rates are relatively low at a stage when lung function is still quite well
preserved [3]. Nevertheless, a recent study states that IPF mortality is increasing in Europe, especially in
Finland and in the UK [4].
Estimation of prognosis is important when choosing patients for lung transplantation and when
considering different therapies. Clinical, biochemical and radiological variables have been proposed for
estimating prognosis. Pulmonary function tests (PFTs), i.e. forced vital capacity (FVC) and diffusing
capacity of the lung for carbon monoxide (DLCO), at diagnosis are most commonly associated with
prognosis [5]. However, a decrease in PFTs within 6 months after diagnosis may have a superior predictive
power [6].
Two drugs, pirfenidone and nintedanib, have now been approved for the prevention of progression of IPF.
Results of clinical trials for up to 1 year with pirfenidone [7] and nintedanib [8] have been published, but
the results may not be applicable to all patients with IPF because of strict inclusion and exclusion criteria.
These trials were not powered to assess the impact on survival. However, pooled analyses and
meta-analyses have suggested a survival benefit [9, 10]. As data on survival of patients with IPF in the
2010s are sparse and the long-term survival benefits of the antifibrotic therapies remain unknown,
observational studies in real-life scenarios are required to facilitate our understanding of the natural history
of IPF and the efficacy of these medications.
Several IPF registries [11–16] have been founded around the world to enhance clinical research and to
enable real-world studies. The Finnish population has had an exceptional history due to geographical and
cultural isolation. The unique genetic background offers special opportunities for research and a national
IPF registry is therefore justified [17]. This IPF registry (FinnishIPF) was initiated in 2011 [18] and it is
currently including patients from all Finnish hospitals that have a pulmonary unit. At present, 700 patients
have been included in the registry and to our knowledge, it is one of the most extensive IPF registries
in the world in relation to population (5.5 million). Despite the numerous IPF registries being built around
the world, the publications are still sparse and more data are needed by clinicians, patients and the
medical industry.
We defined the transplant-free survival and explored the effects of demographic factors, physiological
impairment, antifibrotic therapies and different GAP stages on survival.
Material and methods
Data for this study were collected from the national FinnishIPF registry. This is a multicentre,
observational registry of incident and prevalent IPF patients in Finland. Currently, the registry covers all
Finnish pulmonary clinics in 28 different hospitals.
Patient recruitment to the registry is implemented by screening patients from hospital registries with
International Classification of Diseases (10th Revision) codes J84.1 and J84.9. Diagnoses of IPF are
confirmed by pulmonary specialists and/or multidisciplinary panels. IPF is diagnosed according to ATS/
ERS 2011 criteria [1]. This includes at least exclusion of other known causes of interstitial lung disease by
taking a detailed history of medication and environmental exposures, usually serological testing to exclude
connective tissue disease, measuring spirometry and DLCO, and high-resolution computed tomography.
Bronchoalveolar lavage and surgical biopsies are performed in otherwise unclear cases. At both baseline
and follow-up visits, all examinations and treatment decisions occur as part of routine clinical care without
additional visits or investigations mandated for FinnishIPF.
In the present study, we included patients diagnosed during 2011–2015, resulting in a total of 453 patients.
PFTs were performed according to ERS/ATS standards [19] and repeated when clinically indicated.
Finnish reference values for PFTs were used [20]. In the Finnish population, the predicted values for lung
volumes are higher than those obtained by the 2012 Global Lung Function Initiative predictions for the
Caucasian subgroup for FVC [21]. GAP index was calculated based on gender, age and pulmonary
function [22]. All these data were gathered from the date of diagnosis. A 6-month treatment cut-off was
used to categorise patients as treated or not treated with antifibrotic medicines [23]. The date of death
was obtained from the Population Register Centre in the end of April 2017, and the cause and place
of death were collected from the death certificates. Lung transplantation was considered as an endpoint
equal to death.
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Ethical considerations
A positive statement was received from the Helsinki University Central Hospital Ethical Committee and all
four other university hospitals in Finland. The National Institute of Health and Welfare has given the
authorisation for patient screening from the hospital databases from all Finnish hospitals. All patients have
given their written informed consent. Data are stored in a secure electronic database. Only responsible
doctors and educated study nurses can access the registry with electronic identity verification.
Data analysis
Data analysis was conducted with SAS System for Windows, version 9.4 (SAS Institute Inc., Cary, NC,
USA). The differences in age, FVC % predicted and DLCO % predicted between sexes were tested with
two-sample t-tests. Mean ages between smokers, ex-smokers and nonsmokers were compared using a
one-way ANOVA with Tukey’s test in pairwise comparisons. Transplant-free survival was measured from
diagnosis until death or to the date of transplantation. Survival was evaluated using the Kaplan–Meier
method and differences in survival curves were evaluated using the log-rank test. The associations of
variables with survival were analysed using univariate Cox regression analysis. The significant variables in
the univariate analysis were included into a multivariate Cox regression model. GAP stage was excluded
from multivariate model due to high correlation with FVC % predicted and DLCO % predicted to avoid
collinearity problems.
Results
Altogether 28 centres (five university hospitals, 15 central hospitals and eight regional hospitals) entered
data for 453 patients. The baseline characteristics are presented in table 1. 65% of the patients were male.
At diagnosis, the mean age of the patients was 73.0 years and the age varied from 44 to 91 years. Men
were somewhat younger than women (mean±SD 72.3±8.8 and 74.3±9.3 years, p=0.026). The smokers were
younger at diagnosis than ex-smokers and non-smokers (63.9±9.5, 71.8±8.6 and 75.1±8.3 years,
respectively; one-way ANOVA, p<0.0001). The mean duration of symptoms before diagnosis was
575±799 days and the median duration was 284 days. 56% of the patients were diagnosed within a year
from their first symptoms. At diagnosis, women had better FVC (83.3±18.9% predicted for women,
78.6±17.7% predicted for men; p=0.013) and a trend towards better DLCO (57.9±16.6% predicted for
women, 54.5±16.2% predicted for men; t-test, p=0.063). 22 (5%) patients reported a family history of
pulmonary fibrosis. 64% of patients had two or more comorbidities; 43% had coronary artery disease, 60%
had other cardiovascular diseases, 38% had hypertension, 38% had diabetes, 10% had asthma, 4% had
COPD and 5% had sleep apnoea.
Altogether, 117 (26%) patients received antifibrotic treatment. The mean age and lung function in the
treatment group were lower than those who did not receive medication and men were relatively
TABLE 1 Baseline characteristics
Variable Patients Mean±SD
Age at diagnosis years 453 (100.0%) 73.0±9.0
Male 295 (65.1%) 72.3±8.8
Female 158 (34.9%) 74.3±9.3
BMI kg·m−2 355 (78.4%) 28.4±5.2
<25 93 (26.2%)
25–29.9 147 (41.4%)
>30 115 (32.4%)
Smoking 438 (96.7%)
Never smoker 197 (45.0%)
Ex-smoker 210 (48.0%)
Current smoker 31 (7.0%)
DLCO % predicted 367 (81.0%) 55.6±16.5
FVC L 407 (89.8%) 2.8±0.8
FVC % predicted 407 (89.8%) 80.2±18.2
GAP stage 370 (81.7%)
GAP 1 200 (54.1%)
GAP 2 151 (40.8%)
GAP 3 19 (5.1%)
BMI: body mass index; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity.
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overrepresented in the medication group (table 2). The mean duration between diagnosis and the start of
treatment was 380±416 days. 95 (21%) patients were treated with antifibrotics for >6 months, which we
considered to be a significant enough period to change the progression of the disease. 18 patients had
stopped the medication and four patients had started treatment so late that they were not able to fulfil the
6 months criteria until April 28, 2017. 82 (18%) patients received pirfenidone and 13 (3%) patients
received nintedanib. The mean duration of treatment was 804±416 days. As this was not a clinical trial,
drug compliance was not measured. 13 (3%) patients underwent lung transplantation.
The follow-up time was 3.2±1.4 years after diagnosis, accounting for 1470 person-years. In April 2017, 179
patients had died and 13 underwent a lung transplantation (of whom two died after transplantation)
totalling a transplant-free survival of 58% (261 out of 453) (figure 1). The annualised mortality rate was
13.1%. The cause of death was known in 99% of the cases. The underlying cause of death was IPF in 66%
of patients. The second most common cause of death was cardiovascular disease (in 16% of patients) and
the third most common cause of death was malignant tumour (in 11% of patients) (table 2). 58% of
cancer deaths were due to lung cancer. The median survival time was 4.5 years. Transplant-free survival at
1, 2, 3, 4 and 5 years was 95%, 83%, 70%, 58% and 45%, respectively (figure 1). There was no difference in
survival between men and women (p=0.795), or between smokers, nonsmokers and ex-smokers (p=0.167).
In addition, survival in patients who did not receive antifibrotic medication was similar in both sexes and
in the different smoking groups (data not shown).
In 81% of patients with adequate data for calculations of GAP stage at baseline, it was a predictor of
mortality. In GAP 1 stage, the median survival was not reached; in GAP 2 stage, the median survival was
4.5 years; and in GAP 3 stage, it was 2.2 years (p<0.0001) (figure 2 and table 3). The patients with
>6 months antifibrotic treatment had better survival compared with those who did not receive antifibrotic
treatment (p=0.035) (figure 3). When comparing patients with medication to patients who fulfilled the
lung function criteria for reimbursement (FVC 50–90% predicted) but who had no antifibrotic medication
(n=187), the survival difference remained in benefit of antifibrotic therapy (p=0.031) (figure 4).
In the Cox univariate analysis, age and PFTs at diagnosis were predictors of survival (table 4). However,
sex and smoking status did not predict survival. In the multivariate Cox regression analysis, age, FVC %
predicted and DLCO % predicted were independent factors for survival (table 5). Although patients with
TABLE 2 Characteristics of patients who received antifibrotic treatment and those who did not
Patients with
>6 months treatment
Patients without treatment
or <6 months treatment
Difference
between groups
p-value
Patients 95 358
Age at diagnosis years 67.4±7.8 74.5±8.8 <0.0001
Sex 0.003
Male 74 (77.9%) 221 (61.7%)
Female 21 (22.1%) 137 (38.3%)
BMI kg·m−2 29.0±5.3 28.2±5.1 0.207
Smoking 0.015
Never smoker 31 (33.3%) 166 (48.1%)
Ex-smoker 57 (61.3%) 153 (44.4%)
Current smoker 5 (5.4%) 26 (7.5%)
DLCO % predicted 53.2±14.1 56.5±16.9 0.111
FVC L 2.8±0.7 2.7±0.9 0.338
FVC % predicted 72.4±13.6 82.4±18.7 <0.0001
GAP stage 0.006
GAP 1 33 (40.2%) 167 (58.0%)
GAP 2 46 (56.1%) 105 (36.5%)
GAP 3 3 (3.7%) 16 (5.6%)
Transplantation 7 (7.3%) 6 (1.7%)
Deaths 25 (26.3%) 154 (43.0%)
IPF-related deaths 21 (84.0%) 93 (60.8%)
Data are presented as mean±SD unless otherwise stated. BMI: body mass index; DLCO: diffusing capacity of
the lung for carbon monoxide; FVC: forced vital capacity; IPF: idiopathic pulmonary fibrosis. Bold indicates
statistically significant p-values.
https://doi.org/10.1183/23120541.00170-2018 4
INTERSTITIAL LUNG DISEASE | J. KAUNISTO ET AL.
antifibrotic medication seemed to have better prognosis than those without, the difference was not
significant after age adjustment in the multivariate Cox regression analysis.
Discussion
We present the first data on prognosis, treatment and survival of the incident cases (n=453) in the
FinnishIPF registry. The follow-up accounts for 1476 person-years. The diagnosis of IPF took almost
1.5 years from the first symptoms. During 2011–2017, only a quarter of the patients had received
antifibrotic medicines and the transplantation rate was very low. The 5-year survival rate was 45%. The
independent predictors of survival were age and lung function at diagnosis.
Compared with other registries and clinical trial cohorts [8, 12, 13, 15], our patients were older, and a
greater proportion were men and nonsmokers. Using the Finnish lung function reference values, patients
in the FinnishIPF registry had a milder disease than patients in earlier registry studies. Patients in our
study had better conserved DLCO, which might be explained by the smaller number of smokers or earlier
diagnosis. Compared with the Australian and German registries, the GAP stage was also lower in our
study [12, 15]. As to comorbidities, in our cohort, coronary artery disease and diabetes were more common
while asthma and COPD were less common than in the Australian study [12]. In our study, gastro-
oesophageal reflux was not reported. The differences might be explained by differences in data collection.
Although registries are not the appropriate tool to demonstrate the efficacy of treatment, they provide the
opportunity to monitor disease progression in patients with and without therapy in the real world [21].
The number of patients that received antifibrotic medicines was 23% in the Australian registry, 44% in the
German study and 26% in the present study [12, 15]. In the Australian study, both antifibrotic medicines
were available only during clinical trials, patient access programmes or through private purchase, which
may give rise to bias. During our study, these medicines became available in Finland and they were
reimbursed by the national health insurance. However, in Finland, the prevalence of patients on
antifibrotic medication is much lower than, for example, in Sweden, where the medication is 100%
reimbursed [24]. In Finland, patients pay an annual fee of €572 to receive antifibrotics. As the antifibrotic
FIGURE 1 Kaplan–Meier curve for
transplant-free overall survival of
FinnishIPF registry patients.
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FIGURE 2 Kaplan–Meier analysis
for transplant-free survival according
to GAP stages (log-rank, p<0.0001).
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medicines have several side-effects, we acknowledge that some patients stop the medication before it can
markedly modify the disease progression. In the integrated analysis of clinical studies with pirfenidone,
38.1% patients discontinued pirfenidone due to an adverse event, compared with 14.6% in the placebo
group [25]. Previous real-world studies with pirfenidone or nintedanib reported discontinuation rates of
21–29% [26, 27]. One-sixth of our patients stopped the medication within 6 months. The 6 months
treatment cut-off to categorise patients as treated or not treated was chosen because among the treated,
there were several patients who received antifibrotics only for a short time and inclusion of them into the
treatment group would have resulted to underestimation of the effect of medication. A limit of 1 year
would have resulted in an even greater difference in survival between the groups but would raise questions
about including patients with 1 year treatment in the nontreated group.
In pooled analyses of two multinational phase 3 trials [10] in thoroughly selected patients, the 1-year
mortality was 3.5% in patients who received pirfenidone and 6.7% in the placebo group (p=0.01), and
pirfenidone reduced the risk of death at 1 year by 48%. In separate studies, survival benefit was found
neither with pirfenidone nor nintedanib [7–9]. 1 year is, however, quite a short time to estimate survival
in a chronic illness like IPF. In our study, the patients with >6 months of medication had better overall
survival compared with those who did not receive antifibrotic medicines, but the difference was not yet
seen at 1-year follow-up. This might be explained by the mean delay of 380 days between diagnosis and
the beginning of the treatment. Survival was not measured from the start of medication but from the day
of diagnosis, as in the comparison group, which surely underestimates the effect of the treatment on
survival. The number of lung transplant recipients in our study was low, which might be explained by the
older age of the patients.
In studies from 1998–2005 [28], the 5-year survival rate ranged between 20% and 40%. Now, ∼15 years
later, the prognosis of Finnish IPF patients seems markedly better. One reason for this might be earlier
diagnosis and increased awareness of the disease. Well-preserved lung function implies this, but the
1.5-year time between first symptoms and diagnosis speaks against this. It is also possible that patients
with slow progression are overrepresented in our registry, and patients with a rapid onset of symptoms
and progressive disease may not be included in our study, which is based on screening from registries and
informed consent. In a Finnish single-centre cohort (a registry study without informed consent) of 132
IPF patients from the years 2002–2012, the median survival time was almost equal to our study
(3.75 years) [29].
TABLE 3 Transplant-free survival according to GAP stage
Survival
1 year 2 years 3 years 4 years 5 years
All GAP stages 95% 85% 72% 60% 48%
GAP 1 96% 88% 80% 66% 56%
GAP 2 96% 85% 69% 61% 42%
GAP 3 84% 63% 28% 9% 0%
FIGURE 3 Kaplan–Meier survival
curve for patients treated with
antifibrotics for >6 months versus
patients without antifibrotic treatment
(log-rank, p=0.035).
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In previous registry studies on IPF [12, 15, 16], both prevalent and incident cases were recruited
simultaneously, which may affect survival results. It is known that slowly progressing diseases are
overrepresented in prevalent patients and this induces bias in survival analysis. To avoid this survival bias,
we excluded the prevalent patients from this study. Despite this, the survival rates at 1, 2, 3, 4 and 5 years
of 95%, 83%, 70%, 58% and 45%, respectively, in the present study were quite close to the survival rates in
the Australian registry with 1–4-year cumulative mortality ratea of 5%, 24%, 37% and 44%, although they
also included prevalent patients.
A recent analysis from the US Medicare database [2] indicated that the median survival time in IPF was
3.8 years, with survival time decreasing sharply based on age at diagnosis. Patients between 66 and 69 years
had a median survival of 8 years, compared with 4.5 years in those diagnosed between 75 and 79 years, and
2.5 years in those diagnosed at ⩾80 years. In addition, in our study, age was an independent predictor of
survival, and it was also an explanatory factor for the survival difference between the groups with and
without medication. The effect of sex on survival has been variable; in our study, there was no survival
advantage in women. Smoking has been associated with both increased and decreased mortality [30]. In
our study, no difference was seen in survival between smokers and nonsmokers. In previous studies, high
body mass index (BMI) has been protective against death in IPF [31, 32]. We did not find any correlation
between BMI and survival. GAP stage at diagnosis seemed to work reasonably well in predicting survival.
As our patients were older than in other studies, the better survival is thus explained by better lung
function at diagnosis and lower GAP stage.
There are some limitations to this study. First, we were not able to capture all Finnish IPF patients to the
registry. The patients were included only if they gave the informed consent. It is possible that the patients
with the most aggressive diseases are missing from the registry. Second, we used Finnish reference values
for lung function tests and therefore, the values may not be comparable with other countries. Third,
quality of life was not measured and acute exacerbations were not registered. As in all real-life data,
missing values may have some effect on the reliability of the results. Fourth, the number of patients who
received antifibrotic medicines was low. There were 268 (59%) patients who fulfilled the criterion for
FIGURE 4 Kaplan–Meier survival
curve for patients treated with
antifibrotics for >6 months versus
patients without antifibrotic treat-
ment, among those with forced vital
capacity 50–90% of predicted (log-
rank, p=0.031).
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TABLE 4 Univariate Cox regression analysis for mortality
Variable Patients HR (95% CI) p-value
Age per year 453 1.03 (1.01–1.05) 0.001
Female versus male 453 1.04 (0.78–1.39) 0.794
BMI per kg·m−2 355 0.98 (0.95–1.02) 0.353
Ex/current smoker versus never-smoker 438 1.17 (0.88–1.57) 0.284
DLCO per % predicted 367 0.96 (0.95–0.97) <0.0001
FVC per % predicted 407 0.98 (0.97–0.99) <0.0001
GAP stage 370 1.71 (1.24–2.36) 0.0010
>6 months antifibrotic treatment 453 0.67 (0.46–0.98) 0.037
HR: hazard ratio; BMI: body mass index; DLCO: diffusing capacity of the lung for carbon monoxide; FVC:
forced vital capacity. Bold indicates statistically significant p-values.
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reimbursement (FVC 50–90% of predicted) but only 30% of these patients received antifibrotics for
>6 months. We do not know the reasons for low numbers of treated patients and this detail warrants
further investigation. Antifibrotic medication was not available in Finland until 2013, which may make the
inclusion of patients starting from 2011 to the same survival analysis somewhat artificial. However, this
group can be viewed as a historical control group. There were 32 patients on medication whose diagnosis
was made before 2013. Some of them had been included in a named patient programme starting from
2012. It must also be noted that overall, the median time between the diagnosis and beginning of the
treatment was >1 year. This fact further minimises the error due to the inclusion of patients from the start
of IPF registry in 2011. As a real-world database, the information available was based on clinical practice
and therefore, we cannot make accurate comparisons between treatment groups like in randomised trials.
We also want to highlight the strengths of the study: in Finland, there is a uniform healthcare system
where practically all pulmonary physicians work in public health care. IPF is diagnosed and treated
exclusively in public healthcare centres or hospitals. We have succeeded in recruiting IPF patients from all
of these centres nationwide, resulting in a unique registry of a genetically homogenous population.
Conclusions
Although IPF is diagnosed in Finland at older age, the prognosis is better than expected due to well
preserved lung function. The independent predictors of survival were age and PFTs. Younger age and
better PFTs were also explanatory factors for better survival in patients treated with antifibrotics.
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